BMO Capital Believes Johnson & Johnson (NYSE: JNJ) Still Has Room to Grow

By Jason Carr

In a report released yesterday, Joanne Wuensch from BMO Capital reiterated a Buy rating on Johnson & Johnson (NYSE: JNJ), with a price target of $132. The company’s shares closed yesterday at $130.08, close to its 52-week high of $130.14.

According to TipRanks.com, Wuensch is a 5-star analyst with an average return of 10.6% and a 75.6% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Baxter International.

Currently, the analyst consensus on Johnson & Johnson is Moderate Buy and the average price target is $133.50, representing a 2.6% upside.

In a report issued on May 18, Cowen & Co. also reiterated a Buy rating on the stock with a $143 price target.

The company has a one year high of $130.14 and a one year low of $109.32. Currently, Johnson & Johnson has an average volume of 5.97M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.